Ignite Creation Date:
2024-10-26 @ 3:41 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06623396
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-09-30
Brief Title:
A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase I Trial of Intraperitoneal Mesothelin-Targeted CAR T-Cell Therapy in Patients With Mesothelin-Positive Esophagogastric Adenocarcinoma With Peritoneal Carcinomatosis
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Participants will have a sample of their white blood cells called T cells collected using a procedure called leukapheresis The collected T cells will be sent to a laboratory at Memorial Sloan Kettering to be changed modified to become MSLN-targeted CAR T cells the CAR T-cell therapy that participants will receive during the study Participant study therapy will take about 3-4 weeks
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None